secwatch.observer — SEC 8-K summary
======================================

Issuer:     Landos Biopharma, Inc. (—)
CIK:        0001785345
Form:       8-K
Filed at:   2022-12-16T23:59:59+00:00
Accession:  0000950170-22-026636
Event type: regulatory
Sentiment:  neutral
Materiality: 0.50
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Landos Biopharma gets Nasdaq approval to transfer to Capital Market; 180-day bid price compliance extension
--------------------------------------------------------------------------------

- Transfer from Nasdaq Global Market to Nasdaq Capital Market effective Dec 15, 2022.
- Additional 180-day compliance period granted until June 12, 2023 to meet $1.00 minimum bid price.
- Company may effect a reverse stock split to cure the bid price deficiency if necessary.
- Failure to regain compliance could result in delisting, subject to appeal to a Nasdaq hearings panel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785345/000095017022026636/0000950170-22-026636-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785345/000095017022026636/labp-20221213.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-026636

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer